| 摘要 |
PURPOSE: A bisphosphonate drug for oral administration is provided to enhance bioavailabilitiy of bisphosphonate, to ensure excellent safety, and to treat osteoporosis with improve drug compliance. CONSTITUTION: A bisphosphonate drug for oral administration contains bisphosphonate and inositol hexakisphosphate. The bisphosphonate is alendronate, risedronate, ibandronate, zoledronate, pamidronate, clodronate, tiludronate, cimadronate, or minodronate. A delayed release device is an enteric drug delivery system for pH-dependent drug release. [Reference numerals] (AA) Embodiment 1; (BB) Comparative embodiment 1; (CC) Comparative embodiment 2 |
